If this message displays incorrectly, please view the web page

FEBRUARY 16, 2015

Research Extras


Emory's clinical trials are conveniently displayed on a new website where potential volunteers may easily search for trials for specific health conditions, browse topic areas, and connect to clinical trials coordinators.

New Clinical Trials Website Creates Easy Access to Nearly 1,000 Emory Studies
At a new Emory website, clinicaltrials.emory.edu, potential clinical trials participants will find nearly 1,000 available clinical trials searchable by topic area or health focus. Many trials are seeking volunteers with a particular disease, while others are seeking healthy volunteers. The website and individual trials are available to the entire Emory community and to external participants. Information about each trial includes purpose, timing, investigators, process and eligibility criteria. Links are included to the leader of each trial for registration or additional information. Read more...

Oxytocin – a brain chemical well-known for maternal nurturing and social bonding – acts in a specific brain region of prairie voles, the same as in humans, to promote consoling behavior.
Prairie Voles' Consoling Behavior Could Lead to Autism Insights
Prairie voles, known for forming lifelong, monogamous bonds, show an empathetic, consoling response when other voles are distressed. The research discovery ends a long-standing belief that detecting the distress of others and acting to relieve it is uniquely human. This knowledge could help medical researchers understand and treat disorders in which emotions are interrupted, such as autism spectrum disorder and schizophrenia. Read more...

Transplant surgeons Chris Larsen (Emory School of Medicine Dean) and Tom Pearson (Emory Transplant Center director) played a key role in the development. of belatacept.
Emory Researchers Play Key Role in Development of Better Transplant Drug
The drug belatacept, which controls the immune system and prevents organ rejection after kidney transplant, was found in seven years of data to have a better record of patient and organ survival than calcineurin inhibitors, the previous standard of care. Belatacept was approved by the FDA in 2011 and has been a game changer for treating kidney transplant patients. Read more...

C-reactive protein is a marker of systemic inflammation linked to depression in some patients.
Inflammation Biomarkers Could Guide Depression Treatment
Some patients with depression may respond better than others to drugs that block glutamate, an inflammation-related brain chemical that can be toxic to brain cells at high levels. Markers of inflammation, such as C-reactive protein, could help guide physicians to predict which depressed patients might respond best to glutamate-blocking drugs. Read more...

Editor, Holly Korschun, Executive Director of Research Communications
Managing Editor, David S. Stephens, MD, Vice President for Research